Experimental drug duo targets Tough-to-Treat cancers
NCT ID NCT06911827
Summary
This study is testing whether two new drugs, QLP2117 and QL2107, are safe and effective when given together to patients with advanced solid tumors that have stopped responding to standard treatments. Researchers will enroll 90 patients to find the right dose and see if the combination can shrink tumors. The trial is for people who have tried standard therapies without success or who have no other treatment options available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.